Velcade Mesothelioma (ICORG 05-10) Study

Velcade Mesothelioma (ICORG 05-10) was a Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma.

Preclinical efficacy of Bortezomib in Mesothelioma was promising but the results of this study indicate that Bortezomib monotherapy exhibits insufficient activity to warrant further investigation in unselected patients with Mesothelioma.

For the related Journal Abstract, please click here

Leave a comment